rank,nct_id,title,conditions,interventions
41,NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Drug: Ketoconazole Cream 2%|Drug: Ketoconazole Cream 2% (G&W Laboratories Inc.)|Drug: Placebo
42,NCT03822078,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women",Osteoporosis,Drug: Placebo|Biological: Denosumab
51,NCT03781375,Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis,Juvenile Rheumatoid Arthritis,Drug: Etanercept|Drug: Placebo to Etanerceot|Drug: Methotrexate
52,NCT03780959,Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA),Juvenile Rheumatoid Arthritis,Drug: Etanercept|Drug: Placebo
91,NCT03660787,Efficacy and Dose Ranging Study of Seroguard,Adhesion,Drug: Seroguard|Drug: Placebo
108,NCT03640559,Safety and Tolerability of Seroguard Use,Adhesion,Drug: Seroguard|Drug: Placebos
146,NCT03590613,Phase I Study of GSK2982772 in Japanese Healthy Male Participants,Autoimmune Diseases,Drug: GSK2982772|Drug: Placebo
202,NCT03530631,Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance,Expectancy Versus Pharmacotherapy Effect of Adderall,Drug: Adderall|Drug: Placebo
250,NCT03482713,Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033),Chronic Cough,Drug: Gefapixant 45 mg|Drug: Placebo
289,NCT03453060,Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects,Thrombosis,Drug: E-WE Thrombin- Dose 1|Drug: E-WE Thrombin- Dose 2|Drug: E-WE Thrombin- Dose 3|Drug: E-WE Thrombin- Dose 4|Other: Placebo
298,NCT03445195,Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections,Complicated Urinary Tract Infection|Acute Pyelonephritis,Drug: Sulbactam-ETX2514|Drug: Placebo|Drug: Imipenem-cilastatin
330,NCT03418571,Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection,Respiratory Syncytial Virus Lower Respiratory Tract Infection,Biological: ALX-0171 1.5 mg/kg|Other: Placebo
344,NCT03407430,Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain,Breast Cancer|Lymphoma|Pain,Drug: Pregabalin|Drug: Placebo
379,NCT03374488,Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma,UC (Urothelial Cancer),Drug: Pembrolizumab|Drug: Epacadostat|Drug: Placebo
403,NCT03361865,Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307),UC (Urothelial Cancer),Drug: Pembrolizumab|Drug: Epacadostat|Drug: Placebo
459,NCT03329885,"A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis",Rheumatoid Arthritis|Psoriasis|Ankylosing Spondylitis|Inflammatory Bowel Diseases|Nonalcoholic Steatohepatitis,Drug: BMS-986251|Other: Placebo
511,NCT03305419,A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects,Autoimmune Diseases,Drug: GSK2982772 capsule|Drug: Placebo capsule
520,NCT03301298,Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers,Healthy,Drug: SXC-2023|Drug: Placebo oral capsule
564,NCT03268941,"A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)","Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis",Drug: TAK-906 Maleate|Drug: Metaclopramide|Drug: TAK-906 Maleate Placebo
575,NCT03261167,A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity,"Spasticity, Post-Stroke",Drug: Botulinum toxin A (GSK1358820)|Drug: Placebo
608,NCT03245762,Intranasal Oxytocin for Infants With Prader-Willi Syndrome,Prader-Willi Syndrome,Drug: Oxytocin|Drug: Placebo
609,NCT03245619,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults","Pancreatitis, Acute Necrotizing",Drug: GSK3335065|Drug: Placebo
622,NCT03239483,Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults,HIV Infections,Drug: Dapivirine gel|Drug: Placebo gel
627,NCT03237156,Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants,Japanese Healthy Adult Male Participants,Drug: TAK-906|Drug: TAK-906 Placebo
632,NCT03235726,Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug,"Pulmonary Disease, Chronic Obstructive",Drug: CCI15106|Drug: Placebo
643,NCT03231943,GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers,"Infection, Human Immunodeficiency Virus|HIV Infections",Drug: GSK3640254|Drug: Placebo
649,NCT03228433,"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants",Healthy Participants,Drug: TAK-418|Drug: TAK-418 Placebo
657,NCT03224325,"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants",Healthy,Drug: TAK-831 Tablet T2|Drug: Placebo|Drug: TAK-831 Suspension
755,NCT03171415,"Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers",Obesity|Weight Loss|Overweight and Obesity,Drug: RZL-012|Drug: Placebo
756,NCT03170609,"A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age",Group B Streptococcal Infections,Biological: Multivalent group B streptococcus vaccine|Biological: Placebo
757,NCT03170544,Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001),Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,"Drug: MK-1092, 4.0 nmol/kg|Drug: MK-1092, 8.0 nmol/kg|Drug: MK-1092, 16 nmol/kg|Drug: MK-1092, 32 nmol/kg|Drug: MK-1092, 64 nmol/kg|Drug: Glargine 3.0 nmol/kg|Drug: Lispro 1.2 nmol/kg|Drug: Placebo to glargine|Drug: Placebo to MK-1092|Other: Dextrose|Biological: Insulin"
759,NCT03170193,AMG 529 First in Human Study,Cardiovascular,Drug: AMG 529|Drug: Placebo
787,NCT03159611,Efficacy and Safety Clinical Trial of Tenoten for Children Liquid Dosage Form Therapy in Infants With Sequelae of Perinatal Brain Injury,Sequelae of Perinatal Brain Injury,Drug: Tenoten for children|Drug: Placebo
791,NCT03158038,Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season,Influenza|Healthy,Biological: Monovalent Influenza Vaccine|Other: Placebo
798,NCT03154086,"A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers",Irritable Bowel Syndrome,Drug: GSK3352589|Drug: Matching Placebo
807,NCT03150719,"A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)",Cystic Fibrosis,Drug: Tezacaftor/Ivacaftor|Drug: Ivacaftor|Drug: Placebo
839,NCT03136380,Study of Danirixin in Japanese Healthy Elderly Male Subjects,"Pulmonary Disease, Chronic Obstructive",Drug: GSK1325756H|Drug: Placebo
860,NCT03131167,Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma,Primary Open-angle Glaucoma (POAG)|Ocular Hypertension,Drug: SHP639 (n=60)|Drug: Placebo Comparator (n=24)
861,NCT03129321,"Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis",Tinea Pedis,"Drug: Econazole Nitrate Cream, 1%|Drug: Placebo"
894,NCT03123471,A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp,Psoriasis,Drug: Apremilast|Other: Placebo
907,NCT03119649,A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis,Cystic Fibrosis,Drug: GLPG2222 50 mg|Drug: GLPG2222 100 mg|Drug: Placebo|Drug: GLPG2222 200 mg|Drug: GLPG2222 400 mg
917,NCT03116698,"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period",Actinic Keratosis (AK),Drug: Low dose DFD07 once daily|Drug: High dose DFD07 once daily|Drug: High dose DFD07 twice daily|Drug: Placebo twice daily
952,NCT03102034,"Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age",Respiratory Syncytial Virus Infections,Biological: D46/NS2/N/ΔM2-2-HindIII|Biological: Placebo
973,NCT03097341,Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects,Thrombosis,Drug: xisomab 3G3- Dose 1|Drug: xisomab 3G3-Dose 2|Drug: xisomab 3G3-Dose 3|Drug: xisomab 3G3- Dose 4|Other: Placebo
978,NCT03095651,Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002),Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Biological: MK-5160 16 nmol/kg|Biological: MK-5160 32 nmol/kg|Biological: MK-5160 64 nmol/kg|Biological: Glargine 0.4 U/kg|Biological: Placebo to Glargine|Biological: Placebo to MK-5160|Drug: Dextrose|Biological: Glargine 0.6 U/kg
980,NCT03095599,Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3,"Influenza, Human",Biological: IVACFLU-S|Other: Placebo
989,NCT03091777,Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis,Bacterial Vaginosis,Drug: GDC-229|Drug: Metronidazole Vaginal Gel 0.75%|Drug: Placebo
997,NCT03090100,A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis,Psoriasis,Drug: Guselkumab|Drug: Placebo|Drug: Secukinumab
1026,NCT03075410,First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects,Tuberculosis,Drug: GSK3036656|Drug: Placebo
1081,NCT03055195,Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis,"Dermatitis, Atopic",Drug: Mepolizumab 100 mg|Drug: Placebo matching mepolizumab
1082,NCT03054857,The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery,Oxidative Stress|Cognition Disorders,Drug: Dexmedetomidine|Drug: Placebo
1087,NCT03054428,"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo
1117,NCT03045887,"Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes",Asthma,Drug: GSK2292767 50 μg|Drug: GSK2292767 500 μg|Drug: Placebo
1150,NCT03037541,Cryosurgery and Cream Combination for Actinic Keratosis,Actinic Keratosis,Drug: Carac Cream|Drug: Placebo Cetaphil cream
1170,NCT03032510,Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections,Complicated Urinary Tract Infections,Drug: Eravacycline|Drug: Ertapenem|Drug: Placebo|Drug: Levofloxacin
1191,NCT03028129,Prevention of Tuberculosis in Prisons,"Tuberculosis, Pulmonary|Antibiotic Prophylaxis",Drug: Isoniazid 900 milligrams|Drug: Placebo
1258,NCT03004924,Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo,Bacterial Conjunctivitis,Drug: SHP640|Drug: PVP-I 0.6%|Drug: Placebo
1261,NCT03004638,Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease,Atherosclerosis|Cardiovascular Disease,Drug: MEDI6012 40 mg|Drug: Placebo|Drug: MEDI6012 120 mg|Drug: MEDI6012 300 mg|Drug: Placebo IV Push|Drug: MEDI6012 IV Push
1276,NCT03000608,A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis,Plaque Psoriasis,Drug: SAN021 Serum|Drug: SAN021 Placebo
1283,NCT02998996,"Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU","Influenza, Human","Biological: 15 µg HA/strain and 1% Endocine™|Biological: 15 µg HA/strain and 2% Endocine™|Biological: 15 µg HA/strain|Biological: intramuscular comparator|Biological: intranasal comparator|Biological: Placebo, Saline"
1347,NCT02982187,"A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",Device: Placebo ELLIPTA|Device: Placebo DISKUS|Device: Placebo TURBUHALER|Device: Placebo HANDIHALER|Other: PQ1|Other: PQ2|Other: PQ3|Other: PQ4
1358,NCT02979613,Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed,Chronic Hepatitis B,Drug: TAF|Drug: TDF|Drug: TAF Placebo|Drug: TDF Placebo
1362,NCT02979054,Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking,Keratoconus,Device: T4020|Device: Placebo
1369,NCT02975557,Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD),Dry Eye|Ocular Graft vs Host Disease|Meibomian Gland Dysfunction,Drug: Brimonidine 0.15%|Drug: Brimonidine 0.075%|Drug: Placebo
1411,NCT02967510,"Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy",Vaginal Atrophy,Drug: Estriol|Drug: Placebo
1450,NCT02959983,Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use,Irritable Bowel Syndrome With Diarrhea,Drug: Eluxadoline|Drug: Placebo
1456,NCT02958982,"Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals",Healthy Volunteers|Asthma,Drug: RP3128|Drug: Placebo
1463,NCT02956837,"A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women",Respiratory Syncytial Virus Infections,Biological: RSV Vaccine (GSK3003891A) formulation 1|Biological: RSV Vaccine (GSK3003891A) formulation 2|Biological: RSV Vaccine (GSK3003891A) formulation 3|Drug: Placebo (Formulation buffer S9b)
1487,NCT02951312,"Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug: Glycopyrrolate Inhalation Solution 25mg|Drug: Glycopyrrolate Inhalation Solution 75mg|Drug: Glycopyrrolate Inhalation Solution 200mg|Drug: Glycopyrrolate Inhalation Solution 200mg Jet|Drug: Glycopyrrolate Inhalation Solution 500mg|Drug: Glycopyrrolate Inhalation Solution1000mg|Drug: Placebo
1521,NCT02943460,"Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis",Primary Sclerosing Cholangitis,Drug: Cilofexor|Drug: Placebo to match Cilofexor
1530,NCT02940626,Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.,"Pneumonia, Ventilator-associated|Pneumonia, Staphylococcal",Drug: ASN100|Drug: Placebo
1534,NCT02939326,Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines,Glabellar Frown Lines (GL),Drug: EB-001 injection|Drug: Placebo injection
1556,NCT02935192,Phase 3 Trial of Serbian Seasonal Influenza Vaccine,Influenza,Biological: Vaccine|Other: Placebo
1563,NCT02933879,"Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study",Onychomycosis,Drug: NVXT topical|Drug: Placebo (Vehicle) Topical
1574,NCT02932462,Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis,Scalp Psoriasis,Drug: DSXS|Drug: Placebo
1589,NCT02927457,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects","Lupus Erythematosus, Cutaneous",Drug: GSK2646264 1%|Drug: Placebo
1688,NCT02905331,Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis,Psoriasis,Drug: Guselkumab|Drug: Placebo
1706,NCT02898662,AZD1419 Ph2a Study,Asthma,Drug: AZD1419|Drug: Placebo
1717,NCT02894840,Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults,Influenza,Biological: an inactivated influenza vaccine|Other: Placebo
1728,NCT02890381,"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age",Respiratory Syncytial Virus Infections,Biological: RSV LID cp ΔM2-2 Vaccine|Biological: Placebo
1733,NCT02886702,A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis,Plaque Psoriasis,Drug: Tazarotene Cream 0.05%|Drug: TAZORAC® (tazarotene) Cream 0.05%|Drug: Placebo
1743,NCT02882854,Guanfacine for PONV and Pain After Sinus Surgery,"Postoperative Nausea and Vomiting|Pain, Postoperative",Drug: Guanfacine|Drug: Placebo
1763,NCT02878330,A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.,Respiratory Syncytial Virus Infections,Drug: MEDI8897|Drug: Placebo
1782,NCT02873702,Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis,Erosive Esophagitis,Drug: Dexlansoprazole|Drug: Lansoprazole|Drug: Placebo
1787,NCT02873221,An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine,"Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant|Drug: Usual Care
1795,NCT02871479,A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis,Atopic Dermatitis|Eczema,Drug: SAN007 5% cream|Drug: Placebo|Drug: SAN007 10% cream
1806,NCT02867709,"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant
1836,NCT02858492,"Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)","Arthritis, Rheumatoid",Drug: GSK2982772 60 mg|Drug: Placebo
1850,NCT02854631,Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH),Alcoholic Hepatitis (AH),Drug: Selonsertib|Drug: Prednisolone|Drug: Placebo
1851,NCT02854605,"Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)",Nonalcoholic Steatohepatitis (NASH),Drug: GS-9674|Drug: Placebo to match GS-9674
1909,NCT02838901,Dietary Nitrate Supplements and Ischemic Stroke Recovery,Stroke|Ischemic Stroke|Cerebrovascular Accident,Drug: Beet it Beetroot juice|Drug: Beet It Placebo Beetroot juice
1919,NCT02836249,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China),HBV|Chronic HBV Infections,Drug: TAF|Drug: TDF|Drug: TAF Placebo|Drug: TDF Placebo
1920,NCT02836236,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China),HBV|Chronic HBV Infections,Drug: TAF|Drug: TDF|Drug: TAF Placebo|Drug: TDF Placebo
1952,NCT02828020,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant
1981,NCT02818569,Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic,Sleep|Insomnia,Drug: Dexmedetomidine|Other: Saline Placebo
1990,NCT02817516,"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants",Healthy Volunteers,Drug: TAK-828|Drug: Placebo
1998,NCT02814656,"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects",Chronic Obstructive Pulmonary Disease,Drug: AZD8871|Drug: Placebo
2000,NCT02814565,Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin,Neck Pain|Back Pain|Spasm,Drug: Cyclobenzaprine HCl|Drug: Placebo
2006,NCT02813551,ToRsemide for pOstpartum HYpertension,Preeclampsia,Drug: Torsemide|Drug: Placebo
2057,NCT02798978,"A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects",Cancer|Neoplasms,Drug: GSK1795091|Drug: Placebo
2064,NCT02797522,A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB),Hepatitis B,Drug: ARC-521 Injection|Other: Placebo|Drug: antihistamine|Drug: acetaminophen|Drug: entecavir|Drug: tenofovir
2077,NCT02794870,"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age",Respiratory Syncytial Virus Infections,Biological: RSV LID ΔM2-2 1030s vaccine|Biological: Placebo
2084,NCT02793232,"Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.",Healthy Subjects,Drug: PF-06751979 single dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple ascending dose|Drug: PF-06751979 multiple dose|Drug: Placebo multiple elderly dose
2113,NCT02786927,Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Drug: Placebo ELLIPTA device|Drug: Placebo capsules for use in HANDIHALER device|Other: Inhaler Preference Questionnaire Version 1|Other: Inhaler Preference Questionnaire Version 2
2125,NCT02784704,Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections,Complicated Intra-abdominal Infections|Complicated Appendicitis,Drug: Eravacycline|Drug: Meropenem|Drug: Placebo
2130,NCT02784106,Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: Placebo|Drug: M2951
2136,NCT02782325,Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP),Pouchitis,"Biological: Active FMT, then open label FMT|Biological: Placebo FMT, then open label FMT"
2151,NCT02780388,A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis,Adult Onset Rheumatoid Arthritis,Drug: VIB4920|Other: Placebo
2153,NCT02780167,Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis,Atopic Dermatitis,Drug: PF-04965842|Drug: Placebo
2172,NCT02776033,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis",Psoriasis,Drug: GSK2982772|Drug: Placebo
2173,NCT02775916,"Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome",Primary Sjögren's Syndrome,Drug: CDZ173|Drug: Placebo
2204,NCT02769065,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,Alzheimer Disease|Healthy Volunteers,Drug: TAK-071|Drug: Donepezil|Drug: TAK-071 Placebo|Drug: Donepezil Placebo
2239,NCT02762500,An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis,"Colitis, Ulcerative",Drug: LYC-30937-EC|Drug: Placebo
2262,NCT02758613,A Study of Baricitinib (LY3009104) in Healthy Chinese Participants,Healthy,Drug: Baricitinib|Drug: Placebo
2275,NCT02757105,"Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)",Irritable Bowel Syndrome With Diarrhea,Drug: BEKINDA|Drug: Placebo
2312,NCT02751424,"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830","Infections, Bacterial",Drug: GSK3342830|Drug: Placebo
2331,NCT02748863,Study of Secukinumab With 2 mL Pre-filled Syringes,Psoriasis,Drug: Placebo|Drug: Secukinumab 2 mL form|Drug: Secukinumab 1 mL form
2346,NCT02745392,Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine,Acute Migraine,Drug: ZP-Zolmitriptan|Drug: Placebo
2360,NCT02743117,Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season,Influenza|Healthy,Biological: Monovalent Influenza Vaccine|Other: Placebo
2363,NCT02742766,"Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects",Healthy Volunteers,Drug: GSK3008356|Drug: Placebo
2369,NCT02741687,Sitagliptin in Non-Diabetic Patients Undergoing General Surgery,Hyperglycemia,Drug: Sitagliptin|Drug: Placebo|Drug: Supplemental insulin (insulin lispro)|Drug: Supplemental insulin (insulin aspart)|Drug: Long acting basal insulin (insulin detemir)|Drug: Long acting basal insulin (insulin glargine)
2398,NCT02737722,Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus,Diabetic Foot Infections,Drug: Bisphosphocin Nu-3|Drug: Placebo
2410,NCT02736175,OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery,Post-Surgical Ocular Pain|Post-Surgical Ocular Inflammation,Drug: Dexamethasone|Other: Placebo Vehicle
2457,NCT02730455,Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke,Acute Ischemic Stroke,Drug: natalizumab|Drug: Placebo
2478,NCT02727322,Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery,Pelvic Organ Prolapse,Drug: Nitrofurantoin|Drug: Placebo
2480,NCT02726945,Adipose-derived SVF for the Treatment of Knee OA,Osteoarthritis (OA),Device: GID SVF-2|Other: Placebo
2489,NCT02725515,A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Biological: XmAb5871|Biological: Placebo to match XmAb5871
2493,NCT02724644,EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite),Edematous Fibrosclerotic Panniculopathy|Cellulite,Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Biological: Placebo Comparator
2519,NCT02720523,A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs,Rheumatoid Arthritis,Drug: Placebo|Drug: Upadacitinib
2530,NCT02718898,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis,Genital Psoriasis|Psoriasis,Drug: Ixekizumab|Drug: Placebo
2556,NCT02713789,Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED,Erectile Dysfunction,Drug: hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|Drug: Placebo (PBS-20% sucrose)
2563,NCT02713243,"To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.",Primary Bile Acid Diarrhea,Drug: LJN452|Drug: Placebo to LJN452
2586,NCT02709538,Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Drug: GSP 301 NS|Drug: GSP 301 Placebo NS pH 3.7|Drug: GSP 301 Placebo NS pH 7.0
2591,NCT02709005,Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis,Bacterial Vaginosis,Drug: 5% Monolaurin Vaginal Gel|Other: Placebo
2597,NCT02708355,Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment,Heartburn,Drug: Esomeprazole 20 mg|Drug: Placebo
2602,NCT02708095,A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Drug: Baricitinib|Drug: Placebo
2605,NCT02707640,A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Drug: Matching Placebo|Drug: N-acetylcysteine|Drug: Pirfenidone
2612,NCT02706873,A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate,Rheumatoid Arthritis,Drug: Upadacitinib|Drug: Methotrexate|Drug: Methotrexate Matching Placebo|Drug: Upadacitinib Matching Placebo
2613,NCT02706847,A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs,Rheumatoid Arthritis,Drug: Placebo|Drug: Upadacitinib
2614,NCT02706834,"Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants",Dose Finding Study,Drug: TAK-828|Drug: Placebo
2636,NCT02701985,A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome,Sjogren's Syndrome,Drug: Placebo|Drug: RO5459072
2639,NCT02701634,Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD),Chronic Graft Versus Host Disease,Drug: ENTO|Drug: Placebo
2674,NCT02696798,A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis,Spondyloarthritis,Drug: Ixekizumab|Drug: Placebo
2675,NCT02696785,A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis,Spondyloarthritis,Drug: Ixekizumab|Drug: Placebo|Drug: Adalimumab
2676,NCT02696434,Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL,Opioid Use Disorder,Drug: Naltrexone|Drug: Placebo|Drug: Buprenorphine
2678,NCT02696291,Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects,Viral Infection,Drug: UV-4B 30 mg oral solution|Drug: UV-4B 75 mg oral solution|Drug: UV-4B 150 mg oral solution|Drug: UV-4B X mg (dose to be determined) oral solution|Drug: UV-4B Y mg (dose to be determined) oral solution|Drug: Placebo
2753,NCT02685072,Progesterone Augmentation of Nicotine Replacement Therapy Study,Smoking Cessation,Drug: Progesterone (200 mgs BID)|Drug: Placebo
2761,NCT02684396,"Phase 1, TAK-648, Single-Rising Dose Study",Healthy Volunteers,Drug: TAK-648|Drug: TAK-648 Placebo
2792,NCT02679729,"To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration",Cystic Fibrosis,Drug: AZD5634 for inhalation|Drug: AZD5634 for infusion|Other: Placebo
2817,NCT02675426,A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone,Rheumatoid Arthritis,Drug: Placebo|Drug: Upadacitinib
2830,NCT02672852,BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment,Psoriasis,Drug: Risankizumab|Drug: Placebo
2883,NCT02665260,Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum,Molluscum Contagiosum,Drug: Cantharidin|Drug: Placebo|Device: Gauze occlusion bandage
2889,NCT02664415,Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection,HIV Infections,Biological: VRC01|Biological: Placebo for VRC01
2894,NCT02663687,"Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects",Hereditary Angioedema (HAE),Drug: Recombinant human C1 esterase inhibitor|Drug: Placebo|Drug: SHP623
2895,NCT02663674,Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever),Coccidioidomycosis,Drug: Fluconazole|Other: Placebo
2940,NCT02656485,"A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris",Acne Vulgaris,Drug: B244|Drug: Placebo
2951,NCT02655237,A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids,Uterine Fibroids,Drug: Relugolix|Drug: Relugolix Placebo|Drug: Leuprorelin|Drug: Leuprorelin Placebo
2954,NCT02654717,Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp,Actinic Keratosis,Drug: DFD-07 Cream|Drug: Placebo Cream
2973,NCT02652416,"Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers",Healthy,Drug: BI 1026706|Drug: Placebo
2975,NCT02652260,"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)",HIV-1|Central Nervous System,Drug: MK-1439A - Blinded|Drug: MK-1439A - Open-Label|Drug: ATRIPLA^TM|Drug: Placebo to ATRIPLA™|Drug: Placebo to MK-1439A
2995,NCT02649192,Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children,Healthy Participants,Biological: Influenza virus vaccine|Dietary Supplement: Vitamins A and D|Other: Placebo
3008,NCT02647281,"First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects",Hepatitis B,Drug: GSK3389404|Drug: Matching Placebo
3011,NCT02646566,Study of APD421 as PONV Treatment (Prior Prophylaxis),Postoperative Nausea and Vomiting,Drug: APD421|Drug: Placebo
3022,NCT02643862,Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients,Food Allergy,Drug: Xolair|Drug: Placebo
3039,NCT02642614,"Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD","Pulmonary Disease, Chronic Obstructive",Drug: BI 1026706|Drug: Placebo
3048,NCT02641561,Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis,Post-ERCP Acute Pancreatitis,Drug: Indomethacin|Drug: Lactated Ringer's Solution|Drug: Normal Saline|Drug: Placebo
3050,NCT02641392,A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease,Crohn's Disease,Drug: GED-0301|Other: Placebo
3057,NCT02640482,A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection,Chronic Hepatitis C Virus (HCV) Infection,Drug: ABT-493/ABT-530|Drug: Placebo for ABT-493/ABT-530
3070,NCT02638948,Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: BMS-986142|Drug: Placebo|Drug: Methotrexate
3077,NCT02638103,Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine,Migraine,Drug: Fremanezumab|Drug: Placebo
3089,NCT02635984,Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens,Complications of Bone Marrow Transplant|Hematologic Neoplasms,Drug: Olanzapine|Drug: Placebo
3117,NCT02632786,"The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis",AL Amyloidosis,Drug: NEOD001|Drug: Placebo
3125,NCT02630966,Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease,Crohn's Disease,Drug: Vedolizumab|Drug: Placebo
3136,NCT02629159,A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate,Rheumatoid Arthritis,Drug: Placebo for Adalimumab|Drug: Adalimumab|Drug: Placebo for Upadacitinib|Drug: Upadacitinib
3144,NCT02628028,A Study of LY3337641 in Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: LY3337641|Drug: Placebo
3157,NCT02625974,Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease,Chagas Disease,"Drug: Nifurtimox (Lampit, BAYA2502)|Drug: Placebo"
3183,NCT02623322,A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults,Influenza A,Drug: MHAA4549A|Drug: Placebo
3213,NCT02618759,Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis,Plaque Psoriasis,Drug: DSXS|Drug: Placebo
3215,NCT02618187,"A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis",Ulcerative Colitis,Drug: SER-287|Drug: Placebo|Drug: Placebo Pre-Treat|Drug: Vancomycin Pre-Treat
3245,NCT02614131,A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD),Healthy|Alzheimer's Disease|Mild Cognitive Impairment,Drug: LY2599666|Drug: Solanezumab|Drug: Placebo SC|Drug: Placebo IV
3256,NCT02612909,A Safety and Immunogenicity Study of IVACFLU-A/H5N1,Avian Influenza,Biological: IVACFLU-A/H5N1 vaccine|Biological: Placebo
3257,NCT02612857,Trial of IMO-8400 in Adult Patients With Dermatomyositis,Dermatomyositis,Drug: IMO-8400 Dose Group 1|Drug: IMO-8400 Dose Group 2|Drug: Placebo
3287,NCT02607956,"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV-1 Infection,Drug: DTG|Drug: F/TAF|Drug: B/F/TAF|Drug: DTG Placebo|Drug: F/TAF Placebo|Drug: B/F/TAF Placebo
3288,NCT02607930,"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",HIV-1 Infection,Drug: ABC/DTG/3TC|Drug: B/F/TAF|Drug: ABC/DTG/3TC Placebo|Drug: B/F/TAF Placebo
3290,NCT02607735,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Drug: SOF/VEL/VOX|Drug: Placebo
3312,NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Drug: Lasmiditan 50 mg|Drug: Lasmiditan 100 mg|Drug: Lasmiditan 200 mg|Drug: Placebo
3322,NCT02604173,Altitude Sickness Prevention and Efficacy of Comparative Treatments,Acute Mountain Sickness,Drug: Budesonide|Drug: Acetazolamide|Drug: Placebo
3323,NCT02604160,A Study of LY3113593 in Participants With Chronic Kidney Disease,Chronic Kidney Disease,Drug: LY3113593|Drug: Placebo
3325,NCT02603952,A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza,Influenza,Drug: Oseltamivir|Drug: MEDI8852|Drug: Placebo
3331,NCT02603120,Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed,HIV-1 Infection,Drug: ABC/DTG/3TC|Drug: B/F/TAF|Drug: ABC/DTG/3TC Placebo|Drug: B/F/TAF Placebo
3340,NCT02601560,"To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease",Coronary Artery Disease,Biological: MEDI6012|Biological: Placebo SC|Biological: Placebo IV
3356,NCT02599129,A Study of Secukinumab for the Treatment of Alopecia Areata,Alopecia Areata,Drug: Secukinumab|Drug: Placebo
3362,NCT02598128,"Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)",Exocrine Pancreatic Insufficiency,Device: RELiZORB|Device: Placebo
3363,NCT02598089,Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S),"Influenza, Human",Biological: Trivalent Seasonal Influenza Vaccine|Other: Placebo
3376,NCT02596893,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug: GED-0301|Drug: Placebo
3393,NCT02595073,Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis,Atopic Dermatitis,Drug: DSXS|Drug: Placebo
3424,NCT02589626,Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA,"Diabetes Mellitus, Type 2",Drug: empagliflozin 10mg|Drug: empagliflozin 25 mg|Drug: Placebo
3440,NCT02586025,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,Breast Cancer,Drug: FEC Chemotherapy|Procedure: Surgery|Drug: Docetaxel|Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab
3447,NCT02585700,"A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine","Influenza, Human","Biological: Influenza vaccine, split inactivated|Other: Placebo"
3525,NCT02576951,A Study of Galcanezumab in Healthy Participants,Healthy,Drug: Galcanezumab|Drug: Placebo
3526,NCT02576938,A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Drug: Baricitinib|Drug: Placebo|Drug: Triamcinolone (Optional)
3529,NCT02576639,Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age,Alzheimer's Disease,Drug: CNP520|Drug: Placebo
3551,NCT02573467,"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",Sporadic Inclusion Body Myositis,Drug: Bimagrumab|Drug: Placebo
3555,NCT02573155,"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects",Asthma (Part 1)|COPD (Part 2),"Drug: Dose 1, AZD8871 50 μg (Part 1)|Drug: Dose 2, AZD8871 100 μg (Part 1)|Drug: Dose 3, AZD8871 300 μg (Part 1)|Drug: Dose 4, AZD8871 600 µg (Part 1)|Drug: Dose 5, AZD8871 1200 µg (Part 1)|Drug: Dose 6, AZD8871 1800 μg (Part 1)|Drug: Placebo, AZD8871 placebo (Part 1)|Drug: Treatment A, AZD8871 dose A (Part 2)|Drug: Treatment B, AZD8871 dose B (Part 2)|Drug: Treatment C, Indacaterol 150 μg (Part 2)|Drug: Treatment D, Tiotropium 18 μg (Part 2)"
3601,NCT02566759,"A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants","Schizophrenia, Cerebellar Ataxia",Drug: TAK-831 Oral Suspension|Drug: TAK-831 Placebo|Drug: TAK-831 Tablet
3604,NCT02566369,Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris,Acne Vulgaris,Drug: CD5789 (trifarotene) 50μg/g cream|Drug: Placebo cream
3606,NCT02566265,Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients,Influenza|Multiple Myeloma|Waldenstrom's Macroglobulinemia|Plasma Cell Disorders|MGUS,Biological: Fluzone High Dose Vaccine|Biological: Standard of care/Placebo
3609,NCT02566044,"Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis",Pulmonary Cystic Fibrosis,Other: Placebo|Drug: QBW276
3635,NCT02563106,A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI,Clostridium Difficile|Clostridium Infections,Drug: SYN-004|Drug: Placebo
3643,NCT02561806,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis,Plaque Psoriasis,Drug: Ixekizumab|Drug: Ustekinumab|Drug: Placebo
3644,NCT02561702,Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease,Charcot Marie Tooth Disease,Other: Placebo|Drug: Mexiletine
3647,NCT02561195,A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years,Clostridium Difficile Associated Disease,Biological: Clostridium difficile Vaccine|Biological: Placebo
3648,NCT02561156,TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants,Depressive Disorder,Drug: TAK-653 Placebo|Drug: TAK-653
3676,NCT02556788,Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris,Acne Vulgaris,Drug: CD5789 (trifarotene) 50µg/g Cream|Drug: Placebo Cream
3683,NCT02555878,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,Neoplasms,Drug: Rivaroxaban|Drug: Placebo
3736,NCT02549014,"A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)",Pharmacokinetics,Drug: MK-1064|Drug: Placebo
3737,NCT02548962,Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma,Multiple Myeloma,Drug: Ibrutinib|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Placebo
3747,NCT02547974,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.",Respiratory Disorders,Biological: Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|Biological: Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|Biological: Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|Drug: Placebo
3777,NCT02543892,A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya,Pneumonia,Biological: PATH-wSP|Biological: Placebo
3787,NCT02542605,To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients,Migraine,Drug: Erenumab|Drug: Placebo|Drug: PACAP-38 Challenge Agent
3801,NCT02540265,Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery,"Pain, Post-operative",Drug: N1539|Drug: Intravenous Placebo
3811,NCT02539134,TAK-935 Multiple Rising Dose Study in Healthy Participants,Epilepsy,Drug: TAK-935|Drug: Placebo
3847,NCT02533570,Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus,Systemic Lupus Erythematosus,Drug: Brentuximab vedotin|Drug: Placebo
3859,NCT02532764,Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients,Cystic Fibrosis,Drug: QR-010|Drug: Placebo
3860,NCT02532647,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Colonoscopy,Drug: Remimazolam|Drug: Midazolam|Drug: Placebo
3869,NCT02531633,Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis,Giant Cell Arteritis,Drug: Sirukumab|Drug: Placebo to match sirukumab|Drug: Prednisone|Drug: Placebo to match prednisone
3874,NCT02531035,A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone,Type 1 Diabetes Mellitus (T1DM)|High Level of Sugar (Glucose) in the Blood,Drug: Sotagliflozin|Drug: Placebo
3911,NCT02525094,Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis,Atopic Dermatitis,Biological: MEDI9929|Biological: Placebo
3914,NCT02524561,KEEPS Mammographic Density And Breast Health Ancillary Study,Mammographic Density|Abnormal Mammogram,Drug: CEE pill|Drug: Estradiol patch|Drug: Active Progesterone|Other: Placebo tablet|Other: Placebo patch|Other: Placebo progesterone
3939,NCT02520284,Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis,Ulcerative Colitis,Biological: Andecaliximab|Biological: Placebo
3942,NCT02519842,Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044),Chemotherapy-induced Nausea and Vomiting,Drug: Fosaprepitant|Drug: Placebo for fosaprepitant|Drug: Ondansetron|Drug: Dexamethasone|Drug: 5-HT3 antagonist
3948,NCT02519036,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease",Huntington's Disease,Drug: ISIS 443139 10 mg|Drug: ISIS 443139 30 mg|Drug: ISIS 443139 60 mg|Drug: ISIS 443139 90 mg|Drug: ISIS 443139 120 mg|Other: Placebo
3950,NCT02518971,Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients,Postoperative Urinary Retention,Drug: Tamsulosin|Drug: Placebo
3957,NCT02518113,A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,T-cell Acute Lymphoblastic Leukemia|T-cell Lymphoblastic Lymphoma,Drug: LY3039478|Drug: Dexamethasone|Drug: Placebo
3966,NCT02517515,"ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection",Hepatitis C Virus (HCV),Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
3982,NCT02515669,"Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD",Muscular Dystrophy (DMD),Drug: RO7239361|Drug: Placebo
3983,NCT02515656,Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis,Vaginitis,Drug: POLYGYNAX®|Drug: GYNODAKTARIN®|Drug: Placebo
3984,NCT02515331,Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients,"Patients, Resistant Hypertension",Drug: LHW090|Drug: Placebo
4002,NCT02513550,A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Drug: Ixekizumab|Drug: Placebo
4013,NCT02512575,"A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.",Safety|Tolerability|Pharmacokinetics|Pharmacodynamics|Healthy Subjects|Rheumatoid Arthritis,Drug: AZD9567 Monohydrat|Drug: Placebo oral suspension/ Placebo capsule|Drug: Prednisolone
4027,NCT02511431,Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir,Hepatitis D,Drug: Lonafarnib|Drug: Ritonavir|Other: Placebo
4035,NCT02509117,First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979,Healthy Subjects,Drug: PF-06751979 single ascending dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple dose|Drug: PF-06751979 multiple dose
4041,NCT02508194,A Study to Evaluate the Efficacy of MEDI7510 in Older Adults,Respiratory Syncytial Virus,Biological: MEDI7510|Biological: IIV|Other: Placebo
4067,NCT02504671,Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug: GSK3196165|Drug: MTX|Drug: Folic acid|Drug: Placebo
4095,NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Drug: Reslizumab|Drug: Placebo|Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication|Drug: Oral Corticosteroid (OCS)
4100,NCT02500836,"Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia",Any Ear Nose or Throat Conditions|With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities,Drug: Cocaine HCl 4% Topical Solution|Drug: Cocaine HCl 10% Topical Solution|Drug: Placebo Topical Solution
4129,NCT02497976,Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis,"Cystitis, Interstitial",Biological: Certolizumab pegol|Drug: Placebo
4144,NCT02495844,A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy,Highly Drug-resistant Focal Epilepsy,Drug: UCB0942|Drug: Placebo
4170,NCT02493452,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug: Plecanatide|Drug: Placebo
4177,NCT02492958,"SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults",Staphylococcal Infections,Biological: Staphylococcus aureus 4-antigen vaccine|Biological: Placebo
4186,NCT02491684,"A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection",Asthma,Drug: Interferon beta-1a Nebuliser solution 48 μg/mL|Drug: Placebo
4187,NCT02491463,"A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults",Respiratory Synctial Virus Infections,Biological: GSK3389245A_LD GROUP|Biological: GSK3389245A_HD GROUP|Biological: Bexsero|Drug: Placebo
4195,NCT02490293,Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?,Acute Cholecystitis,Drug: Cephalosporin|Drug: Placebo
4204,NCT02488980,An Evaluation of Weekly Tafenoquine,Falciparum Parasitaemia,Drug: Tafenoquine|Drug: Mefloquine|Drug: Placebo
4229,NCT02486653,Prevention of Post-operative Urinary Retention,Urinary Retention|Urinary Tract Infections,Drug: Tamsulosin|Drug: Placebo
4236,NCT02485717,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,"Drug: spinosad topical suspension, 0.9%|Other: Placebo"
4237,NCT02485704,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,"Drug: spinosad topical suspension, 0.9%|Other: Placebo"
4241,NCT02485301,A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults,Virus Diseases,Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|Drug: Placebo
4246,NCT02484729,"A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males",Safety|Tolerability|Pharmacokinetics|Healthy Subjects,"Drug: AZD9977, oral suspension|Drug: Placebo, oral suspension|Drug: AZD9977, oral solution"
4268,NCT02481141,Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes,"Diabetes Mellitus, Type 2",Drug: 5-ALA-SFC|Drug: Placebo
4291,NCT02477618,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug: SAGE-547|Drug: Placebo
4295,NCT02477332,Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU,Chronic Spontaneous Urticaria,Biological: QGE031|Biological: Omalizumab|Other: Placebo
4317,NCT02474589,"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",Smallpox,Drug: tecovirimat|Other: Placebo
4370,NCT02469298,"Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza",Virus Diseases,Drug: GSK1325756 (Danirixin)|Drug: Placebo To Match GSK1325756|Drug: Oseltamivir Phosphate|Drug: Placebo To Match Oseltamivir Phosphate
4371,NCT02469246,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,HIV-1 Infection,Drug: F/TAF|Drug: ABC/3TC|Drug: ABC/3TC Placebo|Drug: F/TAF Placebo|Drug: 3rd ARV agent
4386,NCT02467075,Double-Blind Placebo-Controlled CIN Trial,Acute Kidney Injury,Drug: Iopamidol 300 (Contrast)|Drug: Placebo (Normal Saline)
4402,NCT02465450,"Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis",Cystic Fibrosis,Drug: JBT-101 (lenabasum)|Other: Placebo
4403,NCT02465437,"Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis",Diffuse Cutaneous Systemic Sclerosis,Drug: JBT-101|Drug: Placebo|Drug: Part B Open-Label Extension
4405,NCT02465216,Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion,Pulmonary Tuberculosis,Other: Placebo|Biological: ID93 + GLA-SE
4435,NCT02461160,"Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study",Healthy Volunteers,Drug: TAK-915 suspension|Drug: Midazolam|Drug: Placebo|Drug: TAK-915 tablet
4478,NCT02454283,Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm,Atrial Fibrillation or Flutter,Drug: Vanoxerine HCl|Drug: Placebo
4501,NCT02452047,Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013),Bacterial Infections,Drug: Imipenem+Cilastatin/Relebactam|Drug: Colistimethate sodium (CMS)|Drug: Imipenem+Cilastatin|Drug: Placebo to CMS
4525,NCT02449291,Study of APD421 as PONV Treatment (no Prior Prophylaxis),Postoperative Nausea and Vomiting,Drug: APD421|Drug: Placebo
4542,NCT02447458,MLN3126 Single Rising Dose Study,Healthy Volunteers,Drug: MLN3126|Drug: MLN3126 Placebo
4548,NCT02446990,Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure,Coronary Artery Disease,Drug: Ivabradine|Drug: Placebo
4585,NCT02443402,Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery,Coronary Artery Disease,Drug: Sitagliptin|Drug: Placebo|Drug: Regular Human Insulin|Drug: Insulin glargine|Drug: Supplemental insulin (Insulin lispro)|Drug: Supplemental insulin (Insulin aspart)
4600,NCT02441218,Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study,Chronic Heart Failure,Drug: Ivabradine|Drug: Placebo
4619,NCT02438787,A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis,Axial Spondyloarthritis,Drug: Placebo|Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg|Drug: Golimumab 50 mg
4625,NCT02437890,A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus,"Lupus Erythematosus, Systemic",Biological: ALX-0061|Biological: Placebo
4629,NCT02437487,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),Clostridium Difficile,Drug: SER-109|Drug: Placebo
4637,NCT02437162,A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis,Axial Spondyloarthritis,Drug: Placebo|Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg|Drug: Golimumab 50 mg
4678,NCT02431754,A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).,Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo|Drug: Alpha1 Blocker
4683,NCT02431468,A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease,Alzheimer's Disease,Drug: Bryostatin 1|Other: Placebo
4688,NCT02431247,A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects,"Immunodeficiency Virus Type 1, Human",Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Drug: DRV/COBI FDC|Drug: FTC/TDF FDC|Drug: D/C/F/TAF FDC - Matching Placebo|Drug: FTC/TDF FDC Matching Placebo|Drug: DRV/COBI FDC Matching Placebo
4690,NCT02430870,TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug: TAK-648|Drug: Placebo
4718,NCT02426918,Study of Debio 1450 for Bacterial Skin Infections,Bacterial Infections,Drug: Debio 1450 IV|Drug: Debio 1450 Oral|Drug: Linezolid|Drug: Debio 1450 Oral Placebo|Drug: Linezolid Placebo|Drug: Vancomycin IV
4728,NCT02424799,"Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264",Urticaria,Drug: GSK2646264 0.5% topical cream|Drug: GSK2646264 1% topical cream|Drug: Placebo
4742,NCT02423577,Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain,Influenza,Drug: FF-3 dry powder|Drug: Placebo
4744,NCT02423408,Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache,Tension-Type Headache,Drug: TNX-201|Drug: Placebo
4763,NCT02421172,"Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients",Hidradenitis Suppurativa (Acne Inversa),Biological: CJM112|Drug: Placebo
4775,NCT02419937,Short-Term Application of Tocilizumab Following Myocardial Infarction,Myocardial Infarction,Drug: Tocilizumab|Drug: Placebo
4786,NCT02418819,"A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia",Schizophrenia,Drug: PF-06412562 3mg BID|Drug: PF-06412562 9mg BID|Drug: PF-06412562 45mg BID|Other: Placebo
4791,NCT02418312,Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer,Peptic Ulcer,Drug: histamine-2 receptor antagonist|Drug: Placebo
4808,NCT02416180,Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler,Asthma,Device: SERETIDE MDI|Device: Placebo DISKUS Inhaler|Device: Placebo MDI
4813,NCT02415439,"A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects",Healthy,Drug: VBP15|Drug: Placebo
4820,NCT02414828,A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB,Tuberculosis,Biological: Placebo|Biological: AERAS-402 3 x 10^8 vp|Biological: AERAS-402 3 x 10^9 vp|Biological: AERAS-402 3 x 10^10 vp
4834,NCT02413255,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers",Healthy Volunteers,Drug: TAK-020|Drug: TAK-020 Placebo
4835,NCT02413229,A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study,Plaque Psoriasis,Drug: DSXS1411|Drug: Placebo
4856,NCT02411539,"Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)",HIV Infections,Biological: VRC01|Biological: Placebo
4866,NCT02410382,Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer,Head and Neck Cancer|Non-small Cell Lung Cancer,Drug: Dexamethasone|Drug: Placebo
4869,NCT02410278,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,Multiple Sclerosis,Drug: dimethyl fumarate|Drug: montelukast|Drug: Placebo
4880,NCT02409459,Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia,Iron Deficiency|Fibromyalgia,Drug: Injectafer|Drug: Placebo
4889,NCT02407223,An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis,"Nonradiographic Axial Spondylitis, Ankylosing",Drug: Group 1: Placebo|Drug: Group 2: Ustekinumab 45 mg|Drug: Group 3: Ustekinumab 90 mg
4900,NCT02406027,An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum,Alzheimer Disease,"Drug: JNJ-54861911, 10 mg|Drug: JNJ-54861911, 25 mg|Drug: Placebo|Drug: JNJ-54861911, 5 mg"
4903,NCT02405442,Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease,Crohn's Disease,Drug: Andecaliximab|Drug: Placebo
4925,NCT02403674,Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021),Human Immunodeficiency Virus (HIV),Drug: MK-1439A|Drug: ATRIPLA™|Drug: Placebo
4952,NCT02400749,Apremilast in Palmo-Plantar Psoriasis,Palmo-plantar Psoriasis,Drug: Apremilast|Drug: Placebo
4965,NCT02398188,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),Central Abdominal Bulging,Drug: LIPO-202|Drug: Placebo
4969,NCT02397694,"Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV-1 Infection,Drug: BIC|Drug: F/TAF|Drug: DTG|Drug: BIC Placebo|Drug: DTG Placebo|Drug: B/F/TAF
5012,NCT02393417,Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris),Warts,Biological: CANDIN|Other: Placebo
5017,NCT02392624,A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria,Urticaria,Drug: Omalizumab|Drug: Placebo
5044,NCT02389881,"Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants",Healthy Volunteers,Drug: TAK-058|Drug: TAK-058 Placebo
5051,NCT02389621,Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures,Chronic Liver Disease|Thrombocytopenia,Drug: Lusutrombopag|Drug: Placebo
5063,NCT02388724,Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis,Erosive Esophagitis,Drug: Vonoprazan|Drug: Lansoprazole|Drug: Vonoprazan Placebo|Drug: Lansoprazole Placebo
5085,NCT02387359,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug: Plecanatide|Drug: Placebo
5159,NCT02377362,"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01","Diabetes Mellitus, Type 2","Drug: GLWL-01, Part A|Drug: Placebo, Part A|Drug: GLWL-01, Part B|Drug: Placebo, Part B|Drug: GLWL-01, Part C|Drug: Placebo, Part C"
5164,NCT02376790,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Drug: Etanercept|Drug: Methotrexate|Drug: Placebo to Etanercept|Drug: Placebo to Methotrexate
5172,NCT02375698,A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB,Tuberculosis,Biological: H56:IC31|Biological: Placebo
5221,NCT02370043,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791",Healthy Volunteers|Insulin Resistance,Drug: KQ-791|Drug: KQ-791 (after meal)|Drug: Placebo
5224,NCT02369835,Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy,Head and Neck Carcinoma|Radiation-Induced Dermatitis,Drug: Dakin's solution|Other: Placebo
5281,NCT02363946,A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD),Alpha-1 Antitrypsin Deficiency,Drug: ARC-AAT Injection|Other: Placebo|Drug: Diphenhydramine
5296,NCT02362321,Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma,"Hematoma, Subdural, Chronic",Drug: Dexamethasone|Other: Placebo
5302,NCT02361476,Does Intraoperative Clonidine Reduce Post Operative Agitation in Children?,Psychomotor Agitation,Drug: Clonidine|Drug: Placebo
5306,NCT02360631,Advancing Tobacco Use Treatment for African American Smokers,Smoking Cessation,Drug: Chantix|Drug: Placebo
5332,NCT02357901,Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine,Opioid Dependence|Opioid Related Disorders,Drug: SUBOXONE|Drug: RBP-6000|Drug: Placebo
5355,NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Drug: Nicotine Spray|Drug: Placebo
5364,NCT02354599,Single-Dose Study of MT203,Healthy Volunteers,Drug: MT203 80 mg or matching Placebo|Drug: MT203 150mg or matching Placebo|Drug: MT203 300 mg or matching placebo
5404,NCT02349477,Gabapentin for Alcohol Relapse Prevention,Alcohol Use Disorder|Alcohol Withdrawal,Drug: Gabapentin|Drug: Placebo
5408,NCT02349360,"Safety, Tolerability and Host Response to Lactobacillus Johnsonii",Healthy,Biological: L. johnsonii N6.2|Biological: Placebo
5409,NCT02349295,A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug: Placebo|Drug: Ixekizumab 80 mg Q4W|Drug: Ixekizumab 80 mg Q2W
5412,NCT02349061,"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","Lupus Erythematosus, Systemic",Drug: Ustekinumab IV|Drug: Placebo Infusion|Drug: Placebo SC|Drug: Ustekinumab SC|Other: Concomitant Medication
5444,NCT02346240,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Biological: Etanercept|Other: Placebo
5453,NCT02345252,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),HIV-1 Infection,Drug: FTC/RPV/TAF|Drug: FTC/RPV/TDF Placebo|Drug: FTC/RPV/TDF|Drug: FTC/RPV/TAF Placebo
5454,NCT02345226,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",HIV-1 Infection,Drug: FTC/RPV/TAF|Drug: EFV/FTC/TDF Placebo|Drug: EFV/FTC/TDF|Drug: FTC/RPV/TAF Placebo
5459,NCT02344407,Partnership for Research on Ebola Vaccines in Liberia (PREVAIL),Ebola Virus,Biological: VSVG-ZEBOV|Biological: ChAd3-EBO Z|Biological: Placebo
5483,NCT02342314,A Study of LY3143753 and LY3185643 in Healthy Participants,Healthy,Drug: LY3143753 (Part A)|Drug: LY3185643 (Part B)|Drug: Placebo (Part A and Part B)|Drug: rGlucagon (Part B)
5522,NCT02338843,A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension,Catecholamine-resistant Hypotension (CRH)|Distributive Shock|High Output Shock|Sepsis,Drug: LJPC-501|Drug: Placebo
5539,NCT02337387,A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women,"Osteoporosis, Postmenopausal",Biological: Blosozumab|Other: Placebo
5541,NCT02337062,Phase IIIb Study of APD421 in Combination as PONV Prophylaxis,PONV,Drug: APD421|Drug: Placebo
5559,NCT02334982,"Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants",Dose Finding Study,Drug: TAK-137|Drug: Placebo
5611,NCT02328404,The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS),Polycystic Ovary Syndrome|Hypovitaminosis D,"Drug: 50,000 IU vitamin D3|Drug: Placebo"
5624,NCT02326298,An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Other: Placebo
5625,NCT02326272,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Other: Placebo
5639,NCT02324335,Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer,Head and Neck Neoplasms|Mucositis,Drug: Brilacidin|Other: Placebo
5643,NCT02323646,Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids,Uterine Fibroids,Drug: Placebo|Drug: Telapristone Acetate
5711,NCT02316470,"Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study",Clostridium Difficile,Biological: VLA84|Biological: Placebo
5751,NCT02312206,"The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis",Primary Systemic (AL) Amyloidosis,Drug: NEOD001|Other: Placebo
5763,NCT02310763,"A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy",Duchenne Muscular Dystrophy,Biological: PF-06252616|Drug: Placebo
5773,NCT02309359,A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Biological: ALX-0061|Other: Placebo|Drug: Methotrexate
5818,NCT02303574,"Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study","Safety, Pharmacokinetics, Pharmacodynamics, Food Effect","Drug: AZD7986, oral solution, 1 to 50 mg/mL|Drug: Placebo, oral solution"
5829,NCT02301988,A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer,Breast Cancer,Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo
5832,NCT02301897,"A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids",Uterine Fibroids,Drug: Telapristone Acetate|Drug: Placebo
5855,NCT02299570,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,Enterocolitis Clostridium Difficile Recurrent,Biological: RBX2660 (microbiota suspension)|Other: Placebo
5885,NCT02296892,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Bronchoscopy,Drug: Remimazolam|Drug: Placebo|Drug: Midazolam
5892,NCT02296320,Study of the Efficacy and Safety of MEDI4893,Staphylococcus Aureus Pneumonia,Drug: MEDI4893|Other: Placebo
5912,NCT02294227,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","Arthritis, Psoriatic",Biological: Secukinumab|Other: Placebo
5914,NCT02293902,A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI),Rheumatoid Arthritis,Drug: Sarilumab SAR153191 (REGN88)|Other: Placebo (for sarilumab)|Drug: Methotrexate|Drug: Folic acid
5915,NCT02293863,A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection,Influenza,Drug: MHAA4549A|Drug: Oseltamivir|Drug: Placebo
5927,NCT02292433,A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy,Type 2 Diabetes Mellitus,Drug: PF-04937319 high dose|Drug: PF-04937319 low dose|Drug: Placebo
5933,NCT02291679,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug: Linaclotide|Drug: Matching Placebo
5941,NCT02290873,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Colonoscopy,Drug: Remimazolam|Drug: Midazolam|Drug: Placebo
5947,NCT02290340,"A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants",Respiratory Syncytial Virus,Drug: Placebo|Drug: MEDI8897 10 mg|Drug: MEDI8897 25 mg|Drug: MEDI8897 50 mg
5953,NCT02289898,"Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",Pancreatic Cancer,Drug: Demcizumab|Drug: Abraxane®|Drug: gemcitabine|Drug: Placebo
5961,NCT02289417,Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis,Ulcerative Colitis,Drug: Apremilast|Drug: Placebo
5974,NCT02287922,A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Biological: ALX-0061|Biological: Placebo|Biological: Tocilizumab
5977,NCT02287779,Safety and Tolerability Study of SHP626 in Overweight and Obese Adults,Non-Alcoholic Steatohepatitis,Drug: SHP626|Drug: Placebo
5982,NCT02287467,Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza,Influenza A|Influenza B,Biological: Intravenous hyperimmune immunoglobulin (IVIG)|Biological: Placebo for IVIG
6035,NCT02282605,Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects,Staphylococcus Aureus Infection,Drug: XF-73 nasal gel|Drug: Placebo nasal gel|Other: Chlorhexidine gluconate 2% topical cloths
6054,NCT02280408,Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002),Ebola Viruses,Other: Placebo|Biological: V920
6060,NCT02280044,Efficacy of Rifaximin in Preventing Campylobacteriosis,Dysentery|Diarrhea|Enteric Campylobacteriosis,Biological: Rifaximin intervention|Biological: Placebo intervention
6086,NCT02277769,Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo (for Dupilumab)
6087,NCT02277743,Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo (for Dupilumab)
6111,NCT02275546,Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063),Contraception: Optional Applicator for Insertion of Vaginal Ring,"Drug: Placebo vaginal ring|Device: Single-use, non-sterile applicator"
6127,NCT02273973,A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),Breast Cancer,Drug: Letrozole|Other: Placebo|Drug: Taselisib
6144,NCT02272725,Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances,Acute Kidney Injury|Exercise-associated Hyponatremia|Perceived Exertion,Drug: Ibuprofen|Drug: Placebo
6158,NCT02271217,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,Post-Ischemic Stroke,Drug: Placebo|Drug: dalfampridine-ER 7.5mg|Drug: dalfampridine-ER 10mg
6174,NCT02269475,A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years,Healthy Japanese Children Age 7 Years Through 18 Years,Drug: MEDI3250|Drug: Placebo
6175,NCT02269423,Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001),Ebola Virus,Biological: V920|Other: Placebo
6178,NCT02268994,KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD,Anemia of Chronic Kidney Disease,Drug: ferric citrate|Drug: Placebo
6184,NCT02268526,Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients,HCMV,Biological: CSJ148|Drug: Placebo
6199,NCT02267382,A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection),Recurrent Vulvovaginal Candidiasis,Drug: VT-1161|Drug: Placebo
6203,NCT02267135,Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis,Chronic Scalp Psoriasis,Biological: Secukinumab 300 mg|Biological: Placebo
6218,NCT02265744,Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus,Lupus,Drug: BMS-931699|Drug: Placebo matching BMS-931699
6219,NCT02265705,A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Drug: Baricitinib|Drug: Placebo
6251,NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS)
6279,NCT02257970,Lymphedema Study for Arm or Leg Lymphedema,Lymphedema,Drug: Ketoprofen|Drug: Placebo
6300,NCT02255760,Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults,MEDI3902 for Prevention of P. Aeruginosa Pneumonia,Drug: MEDI3902 - Dose 1|Drug: MEDI3902 - Dose 2|Drug: MEDI3902 - Dose 3|Drug: MEDI3902 - Dose 4|Other: Placebo
6339,NCT02252016,"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)",Hepatitis C,Drug: Grazoprevir + Elbasvir|Drug: Placebo
6340,NCT02251990,Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067),Hepatitis C,Drug: Grazoprevir/Elbasvir|Drug: Placebo
6371,NCT02248818,AZD8108 SAD/MAD in Healthy Volunteers,Healthy Volunteers,Drug: AZD8108|Drug: Placebo
6403,NCT02246439,BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis,Gastroenteritis|Gastritis,Drug: RHB-102|Drug: Placebo Oral Tablet
6436,NCT02242903,A Study of LY3079514 in Healthy Participants,Healthy Volunteers,Drug: LY3079514|Drug: Placebo
6461,NCT02240121,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug: Rifaximin EIR|Drug: Placebo
6462,NCT02240108,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,Crohn's Disease,Drug: Rifaximin EIR|Drug: Placebo
6487,NCT02237950,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Bacterial Vaginosis,Drug: Metronidazole oral tablets 500mg|Drug: 1% SPL7013 Gel|Drug: Placebo gel
6507,NCT02235064,Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression,"Depression, Postpartum",Drug: Sertraline|Drug: Placebo
6543,NCT02231580,"Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients",Huntington's Disease,Drug: BN82451B|Drug: Placebo
6549,NCT02230761,Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon),Lower Eyelid Steatoblepharon (Excess Eyelid Fat),Drug: XOPH5 Ointment|Drug: Placebo
6552,NCT02230579,Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers,Malaria,Drug: MMV390048 5mg|Drug: MMV390048 20mg|Drug: MMV390048 40mg|Drug: MMV390048 80mg|Drug: MMV390048 120mg|Drug: Placebo to match MMV390048
6576,NCT02228395,"Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers",Healthy,Drug: PF-04958242|Drug: Placebo
6583,NCT02227693,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia",Thrombocytopenia Associated With Chronic Liver Disease,Drug: avatrombopag|Drug: Placebo
6589,NCT02227147,Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK,Neurotrophic Keratitis,Drug: rhNGF 20µg/ml|Other: Placebo
6638,NCT02222714,Safety Evaluation of 3K3A-APC in Ischemic Stroke,Ischemic Stroke,Biological: 3K3A-APC|Drug: Placebo
6650,NCT02221648,Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain,Lower Back Pain,Drug: Placebo|Drug: AbobotulinumtoxinA Treatment
6663,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,Multiple Sclerosis,Drug: fampridine|Drug: Placebo
6671,NCT02219256,"A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants",Autoimmune Disease,Drug: TAK-079|Drug: Placebo to TAK-079
6673,NCT02219048,An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma,Asthma,Drug: Placebo|Drug: PF-03715455
6695,NCT02217475,Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis,Nonalcoholic Steatohepatitis,Drug: Cenicriviroc|Drug: Placebo
6705,NCT02216357,Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease,Aspirin Exacerbated Respiratory Disease (AERD),"Drug: Ifetroban, Oral Capsule|Drug: Placebo, Oral Capsule"
6708,NCT02216123,"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","Malaria, Vivax",Drug: Tafenoquine|Drug: Tafenoquine Placebo|Drug: Chloroquine|Drug: Primaquine|Drug: Primaquine Placebo
6726,NCT02213900,"Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy",Delirium|Cognitive Impairment|Post-traumatic Stress Disorder|Depression|Anxiety,Drug: Haloperidol|Drug: Placebo
6745,NCT02211261,"A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus",Type 2 Diabetes Mellitus,Biological: PF-06293620|Biological: Placebo
6755,NCT02209506,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants",Safety|Tolerability|Pharmacokinetics|Pharmacodynamics,Drug: MLN3126|Drug: MLN3126 Matched Placebo
6784,NCT02207244,A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment,Psoriasis,Drug: Guselkumab 100 mg|Drug: Placebo for guselkumab|Drug: Adalimumab|Drug: Placebo for adalimumab
6785,NCT02207231,A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis,Psoriasis,Drug: Guselkumab 100 mg|Drug: Placebo for guselkumab|Drug: Adalimumab|Drug: Placebo for adalimumab
6825,NCT02203149,Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058),Hepatitis C,Drug: Grazoprevir|Drug: Elbasvir|Drug: Placebo to Grazoprevir|Drug: Placebo to Elbasvir
6844,NCT02201940,Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: Placebo
6855,NCT02201056,"Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935",Healthy Volunteers,Drug: TAK-935|Drug: Placebo
6889,NCT02197065,Pilot Study of Atorvastatin for Orthopedic Surgery Patients,Hip Fracture|Myocardial Ischemia|Inflammation,Drug: Atorvastatin|Drug: Placebo
6898,NCT02196168,Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Verrucous Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Verrucous Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Oral Cavity Verrucous Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Verrucous Carcinoma|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Oral Cavity Verrucous Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Tongue Carcinoma,Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo|Drug: WEE1 Inhibitor AZD1775
6900,NCT02195986,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Atrophic Vaginitis,"Drug: Estradiol Vaginal Cream, 0.01%|Drug: Estrace® 0.01% cream|Drug: Placebo Vaginal Cream"
6913,NCT02195349,"A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis",Psoriasis,Biological: GSK2831781|Biological: Placebo
6952,NCT02190604,"Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients",Cystic Fibrosis,Drug: Placebo|Drug: QBW251
6985,NCT02186873,A Study of Golimumab in Participants With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Drug: Placebo|Drug: Golimumab
7029,NCT02181673,A Study of Golimumab in Participants With Active Psoriatic Arthritis,"Arthritis, Psoriatic",Drug: Placebo|Drug: Golimumab
7057,NCT02178800,"Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults",HIV Infections,Drug: GSK1265744 Tablets|Drug: Injectable GSK1265744|Drug: Placebo for GSK1265744 Tablets|Drug: Injectable Placebo for GSK1265744
7061,NCT02178540,Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients,Cystic Fibrosis,Drug: Placebo|Device: Tobi Podhaler
7075,NCT02176525,Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients,"Hepatitis C, Chronic",Drug: BI 207127 NA|Drug: Placebo
7076,NCT02176486,"Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)",Lupus Nephritis,Drug: Ixazomib|Drug: Placebo
7093,NCT02175225,Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial,Intracerebral Hemorrhage,Drug: Deferoxamine Mesylate|Drug: Placebo (for Deferoxamine Mesylate)
7096,NCT02175121,"Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type II",Drug: Placebo|Drug: PF-06291874
7118,NCT02171819,Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1,Influenza A Subtype H5N1 Infection,"Biological: IVACFLU-A/H5N1, 7.5 mcg|Biological: IVACFLU-A/H5N1, 15 mcg|Other: Placebo Comparator"
7178,NCT02165826,"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD",Chronic Obstructive Pulmonary Disease (COPD),Drug: Roflumilast|Drug: Roflumilast Placebo|Drug: Standard of Care COPD Treatment
7184,NCT02165202,"Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis",Human Immunodeficiency Virus (HIV),Drug: Rilpivirine|Drug: Placebo
7200,NCT02163915,"Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.",Attention-Deficit/Hyperactivity Disorder,Drug: TAK-137|Drug: TAK-137 Placebo
7214,NCT02162758,Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation,Barrett's Esophagus,Drug: Dexlansoprazole|Drug: Dexlansoprazole Placebo
7227,NCT02161406,A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis,Diffuse Cutaneous Systemic Sclerosis,Drug: Abatacept|Drug: Placebo
7255,NCT02159053,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","Spondylitis, Ankylosing",Biological: Secukinumab|Biological: Placebo
7258,NCT02158936,"A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)",Thrombocytopaenia,Drug: Eltrombopag|Drug: Azacitidine|Drug: Placebo
7278,NCT02157506,A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure,Heart Failure|Decompensated Heart Failure|Acute Heart Failure,Drug: CXL-1427|Drug: Placebo
7332,NCT02153112,Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children,Norovirus,Biological: GI.1/GII.4 (15/15)|Biological: GI.1/GII.4 (15/50)|Biological: GI.1/GII.4 (50/50)|Biological: GI.1/GII.4 (50/150)|Drug: Placebo
7333,NCT02153099,"Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants",Dose Finding Study,Drug: TAK-058 (ENV8058)|Drug: Placebo
7346,NCT02151851,A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Biological: Certolizumab Pegol|Drug: Methotrexate|Other: Placebo
7358,NCT02151110,Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults,Healthy Volunteer,Biological: MEDI4920 3 mg|Biological: MEDI4920 10 mg|Biological: MEDI4920 30 mg|Biological: MEDI4920 100 mg|Biological: MEDI4920 300 mg|Biological: MEDI4920 1000 mg|Biological: MEDI4920 3000 mg|Other: Placebo
7389,NCT02148107,Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects,Healthy,Drug: BI 691751|Drug: Placebo
7390,NCT02147899,A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis,Bacterial Vaginosis,Drug: SYM-1219|Drug: Placebo
7400,NCT02147197,A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas,Leiomyoma|Uterine Hemorrhage,Drug: Ulipristal acetate (UPA)|Drug: Placebo
7402,NCT02147158,A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas,Leiomyoma|Uterine Hemorrhage,Drug: Ulipristal acetate (UPA)|Drug: Placebo
7417,NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug: Losmapimod 7.5 mg twice daily|Drug: Placebo twice daily|Drug: Standard therapy
7422,NCT02145182,Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study),Delayed Graft Function,Drug: Eculizumab|Drug: Placebo
7427,NCT02144610,Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia,Critical Limb Ischemia,Biological: HGF Plasmid (AMG0001)|Biological: Matching Placebo
7430,NCT02144285,A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis,"Kidney Failure, Chronic",Drug: LY3113593|Drug: Placebo
7446,NCT02142504,Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults,Norovirus Prevention,Biological: Norovirus Bivalent VLP Vaccine|Drug: Placebo (Saline)
7449,NCT02142153,F901318 Single Ascending Dose Study in Healthy Male Volunteers,Invasive Aspergillosis,Drug: F901318|Drug: Placebo
7476,NCT02139943,A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM),"Diabetes Mellitus, Type 1",Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Placebo
7500,NCT02137772,"Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)",Prevention of CMV Infection or Disease,Drug: Letermovir|Drug: Placebo
7519,NCT02135848,3 Month PHI PAD PoM Study,"Vascular Disease, Peripheral",Drug: GSK1278863|Drug: Placebo
7535,NCT02134314,C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI,End Stage Renal Disease|Kidney Failure|Delayed Graft Function|Ischemic Reperfusion Injury,Drug: C1 Esterase Inhibitor|Drug: Placebo
7572,NCT02131233,"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)",HIV Infection,Drug: Reformulated Raltegravir|Drug: Raltegravir|Drug: TRUVADA™|Drug: Placebo to Reformulated Raltegravir|Drug: Placebo to Raltegravir
7586,NCT02130193,"Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations","Pulmonary Disease, Chronic Obstructive",Drug: Danirixin|Drug: Placebo
7589,NCT02129777,Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis,Plaque Psoriasis,Drug: Namilumab|Drug: Placebo
7608,NCT02127970,Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Drug: Dalbavancin|Drug: Dalbavancin-matching Placebo
7618,NCT02126826,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee",Osteoarthritis,Drug: BI 1026706|Drug: Placebo to BI 1026706
7622,NCT02126306,Beta Glucosylceramide for Treatment of NASH,Compliance Behavior,Drug: Beta Glucosylceramide|Drug: Placebo
7640,NCT02124122,Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru,Healthy,Biological: Lactobacillus reuteri|Biological: Placebo
7647,NCT02123576,Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline,Hepatorenal Syndrome,Drug: Pentoxyfylline|Drug: Placebo|Drug: AMO Therapy
7660,NCT02122471,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug: Plecanatide|Drug: Placebo
7668,NCT02121834,A Study of LY3050258 in Healthy Participants,Healthy Volunteers,Drug: LY3050258|Drug: Placebo
7670,NCT02121795,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,HIV-1 Infection,Drug: FTC/TDF|Drug: F/TAF|Drug: Allowed third antiretroviral agent|Drug: FTC/TDF Placebo|Drug: F/TAF Placebo
7686,NCT02120456,Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis,Actinic Keratosis,Drug: LEO 43204|Drug: Placebo
7688,NCT02120417,A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,Breast Cancer,Drug: Ruxolitinib|Drug: Capecitabine|Drug: Placebo
7693,NCT02120027,52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D),Irritable Bowel Syndrome With Diarrhea,Drug: Ibodutant 10 mg|Drug: Placebo
7698,NCT02119663,A Study of Ruxolitinib in Pancreatic Cancer Patients,Pancreatic Cancer,Drug: Ruxolitinib|Drug: Placebo|Drug: Capecitabine
7704,NCT02119260,"A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients","Oedema, Pulmonary",Drug: GSK2798745 solution|Drug: GSK2798745 suspension|Drug: GSK2798745 capsule|Drug: Placebo solution|Drug: Placebo suspension|Drug: Placebo capsule
7720,NCT02117570,"A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",Clostridium Difficile Associated Disease,Biological: Clostridium difficile vaccine|Biological: Placebo
7722,NCT02117479,Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),Pancreatic Cancer,Drug: Ruxolitinib|Drug: Placebo|Drug: Capecitabine
7733,NCT02116530,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer|Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Olanzapine|Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|Other: Placebo
7739,NCT02115815,A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults,Respiratory Syncytial Virus (RSV),Biological: Placebo|Biological: RSV sF 20 mcg|Biological: MEDI7510 (20 mcg RSV sF)|Biological: RSV sF 50 mcg|Biological: MEDI7510 (50 mcg RSV sF)|Biological: RSV sF 80 mcg|Biological: MEDI7510 (80 mcg RSV sF)
7759,NCT02114268,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults",Respiratory Syncytial Virus Infections,Drug: MEDI8897 Intravenous|Drug: Placebo|Drug: MEDI8897 Intramuscular
7765,NCT02113579,Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity,Dentin Sensitivity,Device: Experimental Mouth Rinse 12027-033|Other: Placebo Mouth Rinse
7794,NCT02110706,BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis,Myasthenia Gravis,Drug: Rituximab|Drug: Placebo
7800,NCT02110225,A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP),Retinitis Pigmentosa,Drug: rhNGF 60 µg/ml eye drops solution|Drug: rhNGF 180 µg/ml eye drops solution|Drug: Placebo
7807,NCT02109484,Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants,Evaluation of a Rotavirus Vaccine,Biological: P2-VP8 Subunit Vaccine 10mcg|Biological: P2-VP8 Subunit Vaccine 30 mcg|Biological: P2-VP8 Subunit Vaccine 60mcg|Other: Placebo
7859,NCT02105688,"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)",Chronic Hepatitis C,Drug: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Drug: Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
7863,NCT02105467,"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)",Chronic Hepatitis C Virus,Drug: Grazoprevir 100mg / Elbasvir 50 mg FDC|Drug: Placebo to Grazoprevir / Elbasvir 50 mg FDC
7876,NCT02104765,A Study of LY2951742 in Healthy Japanese and Caucasian Participants,Migraine Disorders,Drug: LY2951742|Drug: Placebo
7912,NCT02101021,Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,Metastatic Pancreatic Ductal Adenocarcinoma,Drug: Momelotinib|Drug: Placebo to match momelotinib|Drug: Nab-paclitaxel|Drug: Gemcitabine
7916,NCT02100813,Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis,Actinic Keratosis,Drug: LEO 43204|Drug: Placebo
7993,NCT02094937,A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects,Asthma,Drug: Fluticasone Furoate/Vilanterol|Drug: Fluticasone Furoate 100 mcg|Drug: Fluticasone Propionate 250 mcg|Drug: Fluticasone Propionate 100 mcg|Drug: Fluticasone Furoate Placebo|Drug: Fluticasone Propionate Placebo
8009,NCT02093923,"Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects",Hereditary Angioedema,Drug: DX-2930|Drug: Placebo
8011,NCT02093819,"To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers",Healthy,Drug: Placebo to BI 416970|Drug: BI 416970
8029,NCT02092350,Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052),Hepatitis C Virus,Drug: Grazoprevir|Drug: Elbasvir|Drug: Placebo to Grazoprevir|Drug: Placebo to Elbasvir
8052,NCT02091206,A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1),Epilepsy|Dravet Syndrome,Drug: GWP42003-P 5 mg/kg/day Dose|Drug: Placebo control|Drug: GWP42003-P 10 mg/kg/day Dose|Drug: GWP42003-P 20 mg/kg/day Dose
8057,NCT02090764,Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo,Impetigo,Drug: Ozenoxacin|Drug: Placebo
8059,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Drug: dimethyl fumarate|Drug: acetylsalicylic acid|Drug: ASA-Placebo
8068,NCT02089113,OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery,Post-Surgical Ocular Pain|Post-Surgical Ocular Inflammation,Drug: Dexamethasone|Procedure: Placebo Vehicle
8086,NCT02087176,A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,Previously Treated Non Small Cell Lung Cancer,Drug: AZD1775|Drug: AZD1775 Placebo|Drug: Antimitotic Agent|Drug: pegfiligrastim
8192,NCT02076412,A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura,Drug: Fostamatinib Disodium|Drug: Placebo
8193,NCT02076399,A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura,Drug: Fostamatinib disodium|Drug: Placebo
8197,NCT02076178,"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","Infection, Human Immunodeficiency Virus",Drug: 744 Tablet|Drug: 744 LA Injection|Drug: Placebo Tablet|Drug: Placebo Injection
8206,NCT02075541,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.",Respiratory Disorders,Biological: NTHi-10-AS01E|Drug: NaCl Placebo
8208,NCT02075463,Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia,Anemia,Drug: GSK1278863|Drug: Placebo
8245,NCT02072226,A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke,Stroke,Drug: Alteplase|Drug: Alteplase Placebo|Drug: Aspirin|Drug: Aspirin Placebo
8251,NCT02071810,"Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067",Parkinson's Disease (PD),Drug: BIA 9-1067|Drug: Placebo
8259,NCT02070991,Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction,Pulmonary Hypertension,Drug: Macitentan|Drug: Placebo
8263,NCT02070744,"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion",Cystic Fibrosis,Drug: VX-661|Drug: Ivacaftor|Drug: Placebo matched to VX-661|Drug: Placebo matched to Ivacaftor
8276,NCT02069119,"A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)",Atrial Fibrillation,Drug: OPC-108459|Drug: Placebo
8279,NCT02068846,BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent,HIV|Salivary Gland Disease|Benign Lymphoepithelial Lesion,Drug: Ciprofloxacin|Drug: Placebo
8307,NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Drug: Tedizolid (BAY119-2631)|Drug: Placebo Tedizolid (BAY119-2631)|Drug: Linezolid|Drug: Placebo Linezolid
8308,NCT02066389,A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone,Rheumatoid Arthritis,Drug: Placebo|Drug: Upadacitinib
8309,NCT02066298,Steroids In Eosinophil Negative Asthma,Asthma,Drug: Mometasone 220mcg BID|Drug: Tiotropium Respimat 5mcg QD|Drug: Placebo
8311,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Drug: Sorafenib Tosylate
8337,NCT02063659,Telotristat Etiprate for Carcinoid Syndrome Therapy,Carcinoid Syndrome,Drug: Telotristat etiprate|Drug: Placebo
8346,NCT02062801,Prophylactic Ephedrine and Combined Spinal Epidurals for Labor,Labor Pain,Drug: Ephedrine|Drug: Placebo
8355,NCT02062385,"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)",Rotavirus Gastroenteritis,Biological: V260|Biological: Placebo to V260|Biological: OPV|Biological: DTaP
8368,NCT02061202,Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease,Sickle Cell Disease,Drug: Mometasone Furoate|Drug: Placebo
8381,NCT02059434,Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD,Chronic Obstructive Pulmonary Disease (COPD)|Asthma,Drug: LAS190792 Dose 1|Drug: LAS190792 Dose 2|Drug: LAS190792 Dose 3|Drug: LAS190792 Dose 4|Drug: LAS190792 Dose 5|Drug: LAS190792 Dose 6|Drug: LAS190792 Dose 1 (Part 2)|Drug: LAS190792 Dose 2 (Part 2)|Drug: Tiotropium 18 μg|Drug: Indacaterol 150 μg|Drug: Placebo
8383,NCT02059291,Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers,Hereditary Periodic Fevers,Drug: Canakinumab|Drug: Placebo
8398,NCT02058849,Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck,Mucositis,Drug: Beetroot|Other: Placebo
8401,NCT02058589,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant,Herpes Zoster,Biological: Herpes Zoster vaccine GSK1437173A|Drug: Placebo
8411,NCT02058108,"Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection",Chronic Hepatitis B,Drug: Telbivudine|Drug: Placebo
8416,NCT02057835,"Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers",Healthy,Drug: Placebo to BI 691751|Drug: BI 691751 high dose|Drug: BI 691751 middle dose|Drug: BI 691751 low dose 1|Drug: BI 691751 low dose 2
8439,NCT02055638,"Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder",Intermittent Explosive Disorder,Drug: SRX246|Drug: Placebo
8447,NCT02054754,Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects,Safety|Tolerability|Pharmacokinetics|Cancer,Drug: Dexanabinol Dose Level 1|Drug: Dexanabinol Dose Level 2|Drug: Dexanabinol Dose Level 3|Drug: Dexanabinol Dose Level 4|Drug: Dexanabinol Dose Level 5|Drug: Placebo
8468,NCT02052440,Preventing Alcohol Withdrawal Syndrome With Oral Baclofen,Alcohol Withdrawal Syndrome,Drug: Baclofen|Drug: Placebo
8496,NCT02048241,Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder,Intermittent Explosive Disorder|Childhood Aggression|Oppositional Defiant Disorder|Attention Deficit Disorder,Behavioral: Parent Management Training|Other: Placebo|Drug: Intuniv
8515,NCT02046525,Autologous Fecal Therapy,Infectious Disease of Digestive Tract,Biological: Autologous fecal microbiota therapy|Other: Placebo
8528,NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Drug: Solifenacin succinate|Drug: Mirabegron|Drug: Placebo to match solifenacin|Drug: Placebo to match mirabegron
8531,NCT02045732,A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS),Multiple Sclerosis,Biological: PF-06342674 0.25 mg/kg|Biological: Placebo|Biological: PF-06342674 1.5 mg/kg|Biological: PF-06342674 6.0 mg/kg
8540,NCT02044874,A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation,Smoking Cessation,Drug: APD356-lorcaserin hydrochloride|Drug: Placebo
8583,NCT02041325,Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias,Plasma Cell Disorder,Drug: Lenalidomide|Drug: Placebo
8585,NCT02041221,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316",Asthma,Drug: SPARC1316 Dose 1|Drug: Placebo|Drug: SPARC1316 Dose 2|Drug: SPARC1316 Dose 3|Drug: SPARC1316 Dose 4|Drug: SPARC1316 Dose 5
8607,NCT02039427,The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery,Anesthesia Intubation Complication|Tracheal Disease,Drug: Ketorolac|Other: Dexamethasone|Drug: Placebo
8616,NCT02038764,A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Drug: Placebo|Biological: PF-06342674 Dose A|Biological: PF-06342674 Dose B|Biological: PF-06342674 Dose C|Biological: PF-06342674 Dose D
8628,NCT02037555,Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass,Cardiac Surgery|Cardiopulmonary Bypass,Biological: AT-III (Human)|Other: Placebo
8638,NCT02036645,"SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",Mild-Moderate Alzheimer's Disease|Healthy Elderly,Biological: MEDI1814 for IV injection|Biological: MEDI1814 for Subcutaneous Injection|Biological: IV Placebo|Biological: Placebo for Subcutaneous Injection
8639,NCT02036580,D2212C00002 J-Phase II Study,Idiopathic Pulmonary Fibrosis,Biological: tralokinumab cohort 1|Biological: tralokinumab cohort 2|Other: Placebo
8663,NCT02034162,A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants,Helminth Infections,Drug: Mebendazole|Drug: Placebo
8694,NCT02031276,"Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.",Crohn Disease,Drug: risankizumab IV|Drug: risankizumab SC|Drug: Placebo
8713,NCT02029495,"Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis",Psoriatic Arthritis,Drug: 210 mg brodalumab|Drug: 140 mg brodalumab|Drug: Placebo
8720,NCT02028780,"Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects",Healthy,Drug: Placebo to dose|Drug: Idarucizumab|Drug: Placebo to Idarucizumab|Drug: dabigatran
8727,NCT02028065,A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101),Hypersensitivity|Anaphylaxis,Drug: Sugammadex|Drug: Placebo
8756,NCT02024932,"Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy",Spinal and Bulbar Muscular Atrophy,Drug: BVS857|Drug: Placebo
8776,NCT02023099,Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection,Chronic Hepatitis C Infection,Drug: ABT-450/r/ABT-267|Drug: Placebo
8796,NCT02020889,A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis,Churg-Strauss Syndrome,Biological: Mepolizumab|Drug: Placebo
8820,NCT02018887,A Study of LY2969822 in Healthy Participants,Healthy Volunteers,Drug: LY2969822|Drug: Placebo
8829,NCT02017899,"A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.",Shigellosis,Biological: S. sonnei 1790GAHB|Biological: Placebo
8842,NCT02016482,A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis,Nail Psoriasis|Plaque Psoriasis,Biological: Adalimumab|Other: Placebo
8862,NCT02014584,Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia,Alopecia,Drug: Dutasteride|Drug: Placebo
8882,NCT02013388,"MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects",Healthy,Drug: N91115|Drug: Placebo|Drug: Placebo-Day 1 only
8901,NCT02011516,Baclofen Effects on Marijuana Dependence,Marijuana Dependence,Drug: Baclofen|Behavioral: Psychosocial|Drug: Placebo
8924,NCT02008916,"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients","Spondylitis, Ankylosing",Drug: Secukinumab|Drug: Placebo secukinumab
8925,NCT02008890,Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab,Palmoplantar Pustular Psoriasis,Biological: Secukinumab 300mg|Biological: Secukinumab 150mg|Biological: Placebo
8933,NCT02008318,A Study of Galunisertib in Participants With Myelodysplastic Syndromes,Myelodysplastic Syndromes,Drug: Galunisertib|Drug: Placebo
8938,NCT02007720,"Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug: Serelaxin|Drug: Placebo|Other: Standard of CareTherapy
8950,NCT02006888,The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery,Inflammation|Cataracts,Drug: IBI-10090|Drug: Placebo
8981,NCT02005211,"A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers",Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers,Drug: AZD3293|Drug: Placebo
9012,NCT02002702,"Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients",Acute Heart Failure,Drug: Serelaxin|Drug: Placebo
9028,NCT02000817,"Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients","Diabetes Mellitus, Type 1",Biological: Otelixizumab|Biological: Placebo
9038,NCT01999920,Vilazodone for Separation Anxiety Disorder,Separation Anxiety Disorder,Drug: Vilazodone|Drug: Placebo
9040,NCT01999868,Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris,Psoriasis,Biological: Ustekinumab|Biological: Abatacept|Drug: UST Placebo|Drug: ABA Placebo
9041,NCT01999777,Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU,Epilepsy,Drug: USL261|Drug: Placebo
9052,NCT01998984,"Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis",Actinic Keratosis,Drug: ingenol mebutate|Other: Placebo
9063,NCT01998399,Ticagrelor in Severe Community Acquired Pneumonia,"Community Acquired Pneumonia, Severe",Drug: Ticagrelor|Drug: Placebo
9123,NCT01993940,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo
9126,NCT01993849,Use of N-Acetylcysteine (NAC) in Fingernail Biting,Onychophagia,Drug: N-Acetylcysteine (NAC)|Other: Placebo
9144,NCT01991860,US Phase III Study of APD421 in PONV,PONV,Drug: APD421- Amisulpride for IV injection|Drug: Placebo
9145,NCT01991821,European Phase III Study of APD421 in PONV,PONV,Drug: APD421|Drug: Placebo
9148,NCT01991483,A Study of LY2928057 in Hemodialysis Participants,"Renal Insufficiency, Chronic|Kidney Disease, Chronic",Drug: LY2928057|Drug: Placebo
9174,NCT01989468,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,Psoriatic Arthritis,Biological: Secukinumab|Biological: Placebo
9192,NCT01987908,Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease,Sickle Cell Disease,Drug: Aes-103|Other: Placebo
9229,NCT01985425,Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study,Atrial Fibrillation|Thoracic Surgery,Drug: Colchicine|Drug: Colchicine Placebo
9261,NCT01982331,"Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine",Influenza,Biological: LAIV H2N2|Other: Placebo
9262,NCT01982292,Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure,Chronic Heart Failure,Drug: RLX030 (serelaxin)|Drug: Placebo
9264,NCT01982240,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Drug: Plecanatide|Drug: Placebo|Drug: Bisacodyl
9270,NCT01981616,Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab,Inflammatory Bowel Disease,Drug: Vedolizumab|Drug: Placebo|Biological: Hepatitis B vaccine|Biological: Oral cholera vaccine
9290,NCT01980095,ERADICATE Hp - Treating Helicobacter Pylori With RHB-105,Dyspepsia|Helicobacter Pylori Infection,Drug: RHB-105|Drug: Placebo
9363,NCT01974687,Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001),Chronic Hepatitis C,Drug: Uprifosbuvir|Drug: Placebo|Drug: Itraconazole
9382,NCT01973205,Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine,Acute Migraine,Drug: Acetaminophen 250 mg and Aspirin 250 mg|Drug: Placebo
9387,NCT01972776,"A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.",COPD,Drug: QBM076|Drug: Placebo
9397,NCT01972217,Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.,Metastatic Castration-resistant Prostate Cancer,Drug: Olaparib|Drug: Placebo|Drug: Abiraterone|Drug: Prednisone or prednisolone
9400,NCT01972074,Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder,Autism Spectrum Disorder,Drug: Memantine|Other: Placebo
9450,NCT01968135,Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study,Uterine Hemorrhage|Contraception,Drug: Combined Oral Contraceptive Pill|Drug: Placebo Sugar Pill
9451,NCT01968070,A Study of LY3127760 in Healthy Participants,Healthy Volunteers,Drug: LY3127760|Drug: Celecoxib|Drug: Placebo
9453,NCT01967940,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Drug: TAF|Drug: Placebo|Drug: E/C/F/TAF|Drug: Current failing ARV regimen|Drug: ATV
9454,NCT01967888,Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation,Pancreatectomy for Chronic Pancreatitis,Drug: Reparixin|Drug: Placebo
9484,NCT01966120,Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT),Actinic Keratosis,Drug: BF-200 ALA gel|Drug: Placebo to BF-200 ALA gel|Procedure: Photodynamic therapy with BF-RhodoLED
9495,NCT01965652,Long Term Safety of Naldemedine,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo
9498,NCT01965535,Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection,HCV Infection,Drug: LDV/SOF|Drug: RBV|Drug: Placebo to match LDV/SOF|Drug: Placebo to match RBV
9504,NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo
9524,NCT01963403,Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive,"Abnormal Uterine Bleeding, Unspecified|Uterine Bleeding Heavy",Drug: EE 30mcg/LNG 150mcg|Drug: Placebo
9525,NCT01963260,Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001),Immune Thrombocytopenia Purpura,Drug: MK-8723|Drug: Matching Placebo
9555,NCT01960855,A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy,Rheumatoid Arthritis,Drug: ABT-494|Drug: Placebo
9585,NCT01959165,MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients,Ulcerative Colitis,Drug: MEDI7183 low dose|Drug: MEDI7183 medium dose|Drug: MEDI7183 high dose|Drug: Matching Placebo
9592,NCT01958645,"To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.",Healthy Subjects,Drug: MEDI8111|Other: Placebo
9604,NCT01958060,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers",Healthy,Drug: BI 1034020|Drug: Placebo to BI 1034020
9606,NCT01958008,BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis,"Pulmonary Disease, Chronic Obstructive",Drug: Placebo to BI 113608 high dose b.i.d.|Drug: Placebo to BI 113608 low dose b.i.d.|Drug: BI 113608 high dose b.i.d.|Drug: Placebo to BI 113608 medium dose b.i.d.|Drug: BI 113608 low dose b.i.d.|Drug: BI 113608 medium dose b.i.d.
9638,NCT01955720,"Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran",Hemorrhage,Drug: BI 655075|Drug: Placebo
9651,NCT01954927,Pain Management in Children and Young Adults With Sickle Cell Disease,Sickle Cell Disease,Drug: Gabapentin|Drug: Placebo
9660,NCT01954082,Inositol to Reduce Retinopathy of Prematurity,Retinopathy of Prematurity (ROP),Drug: myo-Inositol 5% Injection|Drug: Placebo
9661,NCT01954056,Hydrocortisone for Term Hypotension,"Infant, Newborn, Diseases|Cardiovascular Insufficiency",Drug: Hydrocortisone|Drug: Placebo
9665,NCT01953354,Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis,"Colitis, Ulcerative",Biological: Trichuris suis ova (TSO)|Biological: Placebo
9700,NCT01951105,Effect of L-dopa In Subacute Back Pain Population,Sub-acute Back Pain,Drug: Naproxen|Drug: Carbidopa/Levodopa|Drug: Placebo
9709,NCT01950260,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,Drug: Levothyroxine|Other: Placebo
9721,NCT01949116,Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications,HIV Infections,Drug: LDMTX|Drug: Placebo|Dietary Supplement: Folic acid
9722,NCT01949090,Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older,Influenza,Biological: Investigational H7N1 vaccine GSK2789869A|Biological: Placebo
9807,NCT01942590,Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy,Pompe Disease,Drug: Clenbuterol|Drug: Placebo
9829,NCT01940471,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B,HBV|Chronic HBV Infection,Drug: TAF|Drug: TDF|Drug: TAF Placebo|Drug: TDF Placebo
9831,NCT01940341,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B,HBV|Chronic HIV Infection,Drug: TAF|Drug: TDF|Drug: TAF Placebo|Drug: TDF Placebo
9840,NCT01939314,Sphenopalatine Nerve Block for Headache Tx360,Headache|Migraine,Drug: Bupivacaine|Drug: Placebo
9851,NCT01938664,A Pilot Study of Candesartan as a Treatment for Cocaine Dependence,Cocaine Dependence,Drug: Candesartan with CBT|Other: Placebo with CBT
9869,NCT01937364,Preventing Alcohol Withdrawal With Oral Baclofen,Alcoholism|Alcohol Withdrawal,Drug: Baclofen|Drug: Placebo
9911,NCT01933594,Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load,HIV Infections,Drug: Romidepsin|Drug: Placebo for Romidepsin
9921,NCT01932788,Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation,Vitamin D3 Deficiency,Drug: Vitamin D3 4000 IU in gummy form|Drug: Placebo gummy vitamin
9925,NCT01932437,Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers,Inhalational Anthrax,Biological: ETI-204|Other: Placebo
9927,NCT01932242,"Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers",Inhalational Anthrax,Biological: ETI-204|Other: Placebo
9960,NCT01929863,"Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin","Diabetes Mellitus, Type 2",Drug: GSK2330672|Drug: Placebo|Drug: Metformin
9962,NCT01929707,A Study of LY3050258 in Healthy Participants,Healthy Participants,Drug: LY3050258|Drug: Placebo
9965,NCT01929460,A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration,Pancreatic Cysts,Drug: Ciprofloxacin|Other: Placebo (for ciprofloxacin)
9970,NCT01929226,"Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers",Inhalational Anthrax,Biological: ETI-204|Other: Placebo
